ASCO2014: Ceritinib(LDK378) in advanced ALK+ NSCLC
谁能解释一下，看不太懂这些资料呢 According to updated data presented at the 2014 ESMO Congress, the overall response rate (ORR) was 61.8% and the median progression-free survival (PFS) was 9.0 months. In patients who had not received treatment with a prior ALK inhibitor (n = 83), the ORR with ceritinib was 72.3% with a median PFS of 18.4 months. The ORR was 56.4% and the median PFS was 6.9 months among crizotinib-treated patients (n = 163).
The ORR in patients with brain metastases (n = 124) treated with ceritinib was 55.6%. In patients with measurable brain lesions (n = 29), ceritinib demonstrated tumor shrinkage in approximately 33% of patients. 本帖最后由 阿Q 于 2014-10-9 20:45 编辑
Esmo2014更新的数据：
In April 2014, ceritinib received an accelerated approval from the FDA for the treatment of ALK-positive metastatic NSCLC after initial treatment with crizotinib (Xalkori). This approval was based on data from the phase I single-arm ASCEND-1 trial, which examined ceritinib in 246 patients with NSCLC.
According to updated data presented at the 2014 ESMO Congress, the overall response rate (ORR) was 61.8% and the median progression-free survival (PFS) was 9.0 months. In patients who had not received treatment with a prior ALK inhibitor (n = 83), the ORR with ceritinib was 72.3% with a median PFS of 18.4 months. The ORR was 56.4% and the median PFS was 6.9 months among crizotinib-treated patients (n = 163).
The ORR in patients with brain metastases (n = 124) treated with ceritinib was 55.6%. In patients with measurable brain lesions (n = 29), ceritinib demonstrated tumor shrinkage in approximately 33% of patients.
Esmo2014-LDK378：
样本量是246,ORR 61.8%，中位PFS是9个月。之前未经ALK抑制剂治疗的（83/246)ORR 是72.3%，中位PFS 18.4个月。之前经过crizotinib治疗的（163/246），中位PFS是6.9个月，ORR 56.4%。 脑转（124/246)的ORR是55.6%，其中29人脑转病灶可衡量，缩小约33%。
楼主能不能把这个说得明白一点。一般人看不懂。
页:
[1]